Quick Takeaways
- ARMISTICE CAPITAL, LLC filed SCHEDULE 13G/A for Alto Neuroscience, Inc. Common Stock, $0.0001 par value per share (ANGO).
- Disclosed ownership: 6%.
- Date of event: 31 Dec 2025.
ARMISTICE CAPITAL, LLC - 31 Dec 2025 SCHEDULE 13G/A Report for Alto Neuroscience, Inc. Common Stock, $0.0001 par value per share (ANGO)
- Filing Manager
- ARMISTICE CAPITAL, LLC
- Reporting Manager
- Armistice Capital, LLC
- Symbol
- ANGO
- Shares outstanding
- 27,066,667 shares
- Disclosed Ownership
- 1,624,000 shares
- Ownership
- 6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 21:53:10 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 14 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"ARMISTICE CAPITAL, LLC disclosed 6% ownership in Alto Neuroscience, Inc. Common Stock, $0.0001 par value per share (ANGO) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 14 Aug 2025.
- Current filing was accepted on 17 Feb 2026, 21:53.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Armistice Capital, LLC | 6% | 1,624,000 | 0 | 1,624,000 | /s/ Steven Boyd | Steven Boyd - Managing Member | |
| Steven Boyd | 6% | 1,624,000 | 0 | 1,624,000 | /s/ Steven Boyd | Steven Boyd |